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Although tumor heterogeneity (1) and progression (2) have important biolog- 
ical  implications and therapeutic consequences, little is yet known about basic 
mechanisms of tumor diversification and variant generation. Somatic hybridiza- 
tion between tumor cells and normal host cells has been reported (3) to occur in 
vivo and could potentially contribute to the diversification and generation of 
highly malignant variants. To test this possibility we attempted the in vitro fusion 
of tumor cells with defined normal  host cells such as  macrophages,  which are 
often present within growing tumors. We herein report on two highly metastatic 
hybrid lines independently obtained after in vitro hybridization of a  nonmetas- 
tatic  murine  lymphoma  line  (Eb) (4,  5)  with  syngeneic bone marrow-derived 
macrophages.  Interestingly,  such  high  metastatic  hybridomas  were  found  to 
express a tumor antigen similar to that expressed by spontaneous in vivo derived 
high metastatic variants (ESb) (6-8) of the same tumor. 
Materials and Methods 
The two cell types to be fused were carefully selected. The lymphoma line was made 
thioguanine resistant (EbTGR), and thus HAT (hypoxanthine, aminopterin, thymidine)- 
sensitive, without mutagenesis, by growing it in gradually increasing concentrations of 
thioguanine up to 4 #g/ml, followed by cloning. G-banding caryotype analysis  revealed 
TGR  that the clones were unstable and heterogeneous while the noncloned Eb  line was 
stable, homogeneous, and identical in all eight marker chromosomes with the parental 
line Eb (8).  As fusion partner for the Eb  "rcR line we used in vitro differentiated, bone 
marrow-derived macrophages precuitured for 15 d  in L ceil-conditioned medium. As 
described elsewhere (9), these cultures consisted predominantly of macrophages that were 
highly spread out and had phagocytic activity. Tumor macrophage fusions with polyeth- 
ylene glycol (PEG) (Merck AG, Darmstadt, FRG) (1,000 tool wt; 45% in RPMI, pH 7.5, 
or in 0.15  M  Hepes) were performed with a  modified procedure (10).  Fusion cultures 
a-GR  ro  ha  es  and PEG  consisted of Eb  , mac  p  g  ,  , while control cultures had either Eb  T°R cells 
and PEG, macrophages and PEG, or Eb  vGa cells and macrophages without PEG. 
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Results and Discussion 
From two independent fusion cultures of Eb  a'GR cells and macrophages, two 
hybridomas (Eb-F1  and Eb-F2) were successfully established as HAT-resistant 
lines in tissue culture 40 d postfusion, while nothing was obtained from control 
cultures. The G1 DNA content of these lines was analyzed by a cytofluorograph 
after staining  with  4,6-diamidino-l-phenylindole (DAPI).  It was found to  de- 
crease with time from a  hypotetraploid level at 40 d  postfusion, representative 
of a slightly reduced hybrid, to a diploid (like Eb and ESb), and then hypodiploid 
at 60 d  postfusion (both by Eb-F1  and Eb-F2).  At this stage,  where both lines 
appeared to be fairly well stabilized,  they were cloned. Both the original lines 
and subclones were further investigated. 
Evidence for the hybrid nature of the two cell lines, obtained by cytogenetic 
analysis of G-banded metaphase chromosomes (Fig.  1), consists primarily of the 
presence of normal chromosomes No. 12, which were never found in the parental 
lymphoma line, and which coexisted in the hybrids with the two abnormal forms 
of chromosomes  12  (one translocated,  12  +, and one  deleted,  12-  [8]) of the 
iymphoma line. Apart from the additional normal chromosome 12, the hybrid 
lines carried several new marker chromosomes not found in the parental Eb  "rGR 
cells. The high metastatic in vivo variant ESb did not contain a normal chromo- 
some 12 and carried a  marker chromosome with a  fragment from 12  that was 
not found in Eb-F1 or Eb-F2 cells. 
FIGURE  1.  Analysis performed on 25 G-banded metaphases per cell line, giving numbers of 
normal or abnormal No.  12 chromosomes found in 90-100% of the metaphases. No.  12  + and 
12-  forms appeared  in  two  subtypes.  Their presence  in each  cell  line is indicated by  the 
symbols &, I', and A, V, respectively. (*) 70% of the metaphases with one and 30% with two 
chromosomes. (i) 50% of the metaphases with one and 50% with two chromosomes. LARIZZA  ET  AL.  BRIEF  DEFINITIVE  REPORT  1581 
The new lines Eb-F1 and Eb-F2 were inoculated subcutaneously into syngeneic 
DBA/2 mice and compared with the parental Eb  xcR line for tumorigenicity and 
metastatic capacity (Fig.  2).  Mice inoculated with the parental  line developed 
large primary tumors and died after ~6 wk, without overt metastases. In contrast, 
mice inoculated with the tumor-macrophage hybridomas died after only ~10- 
14 d, with small primary tumors and metastases in liver, lung, and spleen. Similar 
results were obtained in three separate experiments and also with subclones Eb- 
F 1  F1  and Eb-F2C4 (Fig.  2),  consistently demonstrating the acquisition of high 
metastatic capacity by the somatic cell hybrids. EB-F 1 cells isolated from in vivo 
tumors were cytogenetically similar to those from tissue culture. 
Next we investigated cell surface marker expression to compare the new in 
vitro generated variants with the original in vivo derived high metastatic variant 
ESb (Fig. 2). Tumor-associated transplantation antigens (TATA) were typed in 
vitro as described (6,  7,  1 I), using syngeneic, tumor-specific, cytotoxic T  lym- 
phocytes (CTL). This analysis clearly revealed that the in vitro generated high 
metastatic variants expressed a TATA different from that of the parental Eb  TGR 
cells  and  similar  to  that  of ESb  type  cells  (i.e.,  TATA2).  It  was  previously 
demonstrated (11) that the ESb TATA was a  distinct marker of this cell line 
which was not expressed on any other syngeneic or allogeneic tumor line tested. 
Eb-F 1 and Eb-F2 cells also showed, similar to ESb type cells, a high expression 
of Fc  receptors  (12),  as  detected  in  an  EA  rosette  assay,  while  Eb  TGR  cell 
expression was low.  The pattern of expression of T  lymphoid differentiation 
antigens (Thy-1, Lyt-1, Lyt-2) also changed on the hybrid lines, but not exactly 
the same way as on ESb type cells. While all three markers were expressed on 
Eb-F1  and Eb-F2 cells,  Eb  TGR  cells expressed predominantly Thy-1  and Lyt-2 
while  ESb  cells  expressed  predominantly  Lyt-1,  as  reported  previously (13). 
Taken together, the profiles of marker expression (Fig. 3) show (a) the profound 
changes that took place after fusion of Eb  TGR cells with macrophages, and (b) the 
similarities to the changes seen in  vivo during progression of Eb to  ESb type 
cells. 
Fig. 2 also shows the mortality curves from mice inoculated with Eb  TGR cells 
to which small numbers of ESb type cells had been added. A  pronounced shift 
in the mortality curves was observed (Fig.  2) even when as few as 10  ESb cells 
were added to 106 Eb  xcR cells. This shows that the metastatic tumor cells could 
not  have  preexisted  in  the parental  Eb  TGR  cell  line  because this  would  have 
resulted in a shift in the mortality curve. 
Our  findings demonstrate that  the fusion of a  nonmetastatic tumor with a 
bone marrow-derived normal host cell (macrophage) can lead to the generation 
of highly metastatic tumor variants.  The relatively quick segregation of chro- 
mosomes after fusion leads to additional cellular heterogeneity, thus increasing 
even further the material from which the best-fitted variants could be selected 
by the host (14). That such a mechanism could indeed be an important parameter 
in tumor progression is suggested by recent findings from other tumor systems 
(15,  16).  Not all somatic cell fusions, of course, may give rise to viable prolifer- 
ating hybrids. We have observed with a different tumor line that not all hybri- 
domas with normal cells will lead to generation of high metastatic variants (17). 
Intensive further studies along these lines are required to define which properties 1582  LARIZZA  ET AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE 2.  Survival curves of DBA/2J mice after subcutaneous inoculation of 106 cells of the 
high metastatic tumor macrophage hybridomas Eb-F1 and Eh-F2 (groups VII, VIII) (bottom) 
in comparison (top) to those of the low metastatic parental T  lynfphoma Eb  TGa (group I) and 
its spontaneous high metastatic in vivo variant ESb (group VI). Data from clones of Eb-F1 (Eb- 
F1F1), and Eb-F2 (Eb-F2C4) are included (groups IX and X). Groups II-IV show the shifts in 
the survival curves when small numbers of ESb cells were added to the Eb  Tea cells. Arrows 
point out the 50% survival time in each group. LARIZZA  ET  AL.  BRIEF  DEFINITIVE  REPORT  1583 
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FIGURE 3.  Cell  surface marker expression by the high metastatic tumor macrophage hybri- 
domas Eb-F  1 and Eb-F2 in comparison with the low metastatic parental T lymphoma EbTG  g 
and the spontaneous high metastatic in vivo variant ESb. (1) Tumor-associated transplantation 
antigens type 1 (TATAr) were typed using syngeneic tumor-specific cytotoxic T lymphocytes 
(CTL) raised against Eb type cells, and those of type 2 (TATA=) by using CTL raised against 
ESb type cells (10, 14). Values are expressed as percent specific  5~Cr release from the respective 
target cells (T) after 4 h co-incubation of CTL and T at the indicated ratios. (2) Expression of 
lymphoid differentiation antigens was tested by monoclonal antibodies and cytofluorographic 
analysis as described (16). Columns indicate the percentage o£ specifically stained cells. (3) 
Percentage of EA rosette-forming cells tested as described (15). The original Eb lymphoma 
line is not shown because it had the same profile of marker expression as the Eb  TGR cells. 
contributed  by  either  tumor  cells  or  host  cells  are  important  for  metastatic 
potential  and  how  the  expression  of these  properties  can  be  regulated  and 
modulated. 
Summary 
A  low metastatic, thioguanine-resistant murine T  lymphoma line (Eb  "rGR) was 
hybridized in  vitro, with the help of polyethylene glycol, with syngeneic bone 
marrow-derived macrophages. Two HAT-resistant hybrid lines (Eb-F1 and Eb- 
F2)  were  obtained  from  independent  fusion  cultures.  A  cytogenetic analysis 
revealed that most of the macrophage chromosomes except No.  12 had segre- 
gated or become rearranged 60 d  after fusion, a  time at which the cell lines had 
become stabilized in culture. Syngeneic mice inoculated subcutaneously with the 
tumor macrophage hybrid lines developed, very quickly, visceral metastases and 
died after <2 wk, while those inoculated with the parental line lived for >6 wk 
and developed only localized, large primary tumors. The metastatic hybridomas 
expressed  a  similar  tumor  antigen  as  a  spontaneous,  in  vivo  derived,  high 
metastatic variant (ESb) of the same tumor.  This suggests that ESb cells might 
have arisen from a spontaneous fusion with a host macrophage. 
We thank Dr. M. St6hr, Heidelberg, for help with the cytofluorometric DNA analysis, 
and Mrs. Heidrun Zimmermann for typing assistance. 1584  LARIZZA  ET AL.  BRIEF  DEFINITIVE REPORT 
Received for publication 30 May 1984 and in revised form 3 August 1984. 
References 
1.  Heppner, G. H., and B. E. Miller. 1983. Tumor heterogeneity: biological implications 
and therapeutic consequences. Cancer Metas. Rev. 2:5. 
2.  Foulds, L.  I969,  1975. Neoplastic Development. Volumes 1 and 2. Academic Press, 
Inc., New York. 
3.  Ber, R., F. Wiener, and E. M. Feny6.  1978. Proof of in vivo fusion of murine tumor 
cells with  host cells by universal fusers: brief communication. J.  Natl.  Cancer Inst. 
60:931. 
4.  Parr,  I.  1972.  Response  of syngeneic  murine  lymphomata to  immunotherapy  in 
relation to the antigenicity of the tumor. Br. J. Cancer.  26:174. 
5.  Schirrmacher, V., G. Shantz, K. Clauer, D. Komitowski, H.-P. Zimmermann, and M. 
L.  Lohmann-Matthes.  1979.  Tumor  metastases and  cell-mediated  immunity in  a 
model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastases formation 
in vivo. Int. J. Cancer.  23:233. 
6.  Schirrmacher,  V.  1979.  Tumor metastases and cell-mediated immunity in a  model 
system  in  DBA/2  mice.  V.  Transfer  of protective  immunity  with  H-2  identical 
immune T  cells from B10.D2 mice. Int. J. Cancer.  24:80. 
7.  Schirrmacher, V., and K. Bosslet. 1980. Tumor metastases and cell-mediated immu- 
nity  in  a  model  system  in  DBA/2  mice.  X.  Immunoselection of tumor  variants 
differing in tumor antigen expression and metastatic capacity. Int. J. Cancer.  25:781. 
8.  Dzarlieva, R., V. Schirrmacher, and N. Fusenig.  1982. Cytogenetic changes during 
tumor progression towards invasion, metastasis, and immune escape in the Eb/ESb 
model system. Int. J. Cancer.  30:633. 
9.  Meerpohl, H.J.G., M.-L. Lohmann-Matthes, and H. Fischer.  1976. Studies on the 
activation of mouse bone marrow-derived macrophages by the macrophage cytotox- 
icity factor (MCF). Eur. J. Iramunol. 6:213. 
10.  Brahe C., and A. Serra.  1981. A simple method for fusing human lymphocytes with 
rodent cells in monolayer by polyethylene glycol. Somatic Cell Gen.  7:109. 
I I.  Bosslet,  K.,  V.  Schirrmacher,  and  G.  Shantz.  1979.  Tumor  metastases  and  cell- 
mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns 
of protective anti-tumor immunity in vivo and of cytolytic T  cells in  vitro. Int. J. 
Cancer.  24:303. 
12.  Schirrmacher, V., and W. Jacobs. 1979. Tumor metastases and ceil-mediated immu- 
nity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc receptors 
on metastatic tumor cell variants. J. Supramol. Struct.  11:105. 
13.  Altevogt, P., J. T. Kurnick, A. K. Kimura, K. Bosslet, and V. Schirrmacher.  1982. 
Different expression of Lyt differentiation antigens and cell surface glycoproteins by 
a murine T  lymphoma line and its high metastatic variant. Eur. J. Immunol.  12:300. 
14.  Larizza, L., and V. Schirrmacher.  1984.  Somatic cell fusion as a source of genetic 
rearrangements leading to metastatic variants. Cancer Metas. Rev. In press. 
15.  De Baetselier, P., E. Gorelik, Z. Eshhar, Y. Ron, S. Katzav, M. Feldman, and S. Segal. 
1981. Metastatic properties conferred on non-metastatic tumors by hybridization of 
spleen B lymphocytes with plasmacytoma cells. J. Natl. Cancer Inst. 67:1079. 
16.  Kerbel, R. S.,  A.  Lagarde, J. w.  Dennis, and T.  P.  Donaghue.  1983.  Spontaneous 
fusion in vivo between normal cells and tumor cells:  possible contribution to tumor 
progression and metastasis studied  with a  lectin resistant mutant tumor. Mol.  Cell. 
Biol.  3:523. 
17.  Larizza, L., V. Schirrmacher, M. St6hr, E. Pfl/iger, and R. Dzarlieva. 1984. Inherit- 
ance of immunogenicity and metastatic potential in murine cell hybrids from the T 
lymphoma ESb 08 and normal splenic lymphocytes. J. Natl. Cancer Inst. 72:137 I. 